Cochrane · systematic review · CD011376
Interventions for the management of fatigue in adults with a primary brain tumour
Day, J, Yust-Katz, S, Cachia, D, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
22
current version
GRADE rated
22
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 18 · 81.8%Low 4 · 18.2%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyBoele 2013: modafinil compared with placebo for fatigue in people with a primary brain tumour
Population: people with a primary brain tumour
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Fatigue –concentration problems Subscale from CIS Boele 2013: modafinil vs placebo | no estimate extracted | 1 study · 37 participants | Very low |
Fatigue –reduced motivation Subscale from CIS Boele 2013: modafinil vs placebo | no estimate extracted | 1 study · 37 participants | Very low |
Fatigue –reduced activity Subscale from CIS Boele 2013: modafinil vs placebo | no estimate extracted | 1 study · 37 participants | Very low |
Fatigue –severity Subscale from CIS Boele 2013: modafinil vs placebo | no estimate extracted | 1 study · 37 participants | Very low |
Adverse events ( Boele 2013: modafinil vs placebo | RR 2.79 [0.59, 13.16] | 1 study · 37 participants | Very low |
Laigle‐Donadey 2019: dexamfetamine sulfate compared with placebo for fatigue in primary brain tumour
Population: people with a primary brain tumour
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Fatigue MFI‐20 scale ( Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo | no estimate extracted | 1 study · 41 participants | Very low |
Fatigue ('asthenia') Norris Scale Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo | no estimate extracted | 1 study · 41 participants | Very low |
Cognition Trail Making Test A Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo | no estimate extracted | 1 study · 41 participants | Very low |
Cognition Trail Making Test B Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo | no estimate extracted | 1 study · 41 participants | Very low |
Cognition Semantic Fluency Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo | no estimate extracted | 1 study · 41 participants | Very low |
Cognition Lexical Fluency Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo | no estimate extracted | 1 study · 41 participants | Very low |
Cognition Episodic memory (Grober and Buschke test) Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo | no estimate extracted | 1 study · 41 participants | Very low |
Cognition Mattis Scale Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo | no estimate extracted | 1 study · 41 participants | Very low |
Affectivity Norris Scale Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo | no estimate extracted | 1 study · 41 participants | Very low |
Apathy Marin Scale Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo | no estimate extracted | 1 study · 41 participants | Very low |
Depression HADS Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo | no estimate extracted | 1 study · 41 participants | Very low |
Quality of life EORTC QLQ‐C30 Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo | no estimate extracted | 1 study · 41 participants | Very low |
Quality of life EORTC QLQ‐BN 20 Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo | no estimate extracted | 1 study · 41 participants | Very low |
Porter 2020: armodafinil compared with placebo for fatigue in high‐grade glioma
Population: people with primary brain tumour
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Fatigue Brief Fatigue Inventory (number of participants with an improvement in 2 points from baseline at 8 weeks (%)) Porter 2020: armodafinil vs placebo | no estimate extracted | 1 study · 297 participants | Low Downgraded: risk of bias |
Cognition Symbol Digit Modalities Test (median (range)) Porter 2020: armodafinil vs placebo | no estimate extracted | 1 study · 180 participants | Low Downgraded: risk of bias |
Quality of life Linear Analogue Self Assessment (median (range)) Porter 2020: armodafinil vs placebo | no estimate extracted | 1 study · 232 participants | Low Downgraded: risk of bias |
Adverse events Grade 3 or higher (number of participants (%)) Porter 2020: armodafinil vs placebo | no estimate extracted | 1 study · 328 participants | Low Downgraded: risk of bias |
Modafinil compared with placebo for fatigue in people with a primary brain tumour
Population: people with a primary brain tumour
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Fatigue ‐ concentration problems Sub‐scale from Checklist Individual Strength Scale from: 0 to 35 ( Modafinil vs placebo | no estimate extracted | 1 study · 37 participants | Low |
Fatigue ‐ reduced motivation Sub‐scale from Checklist Individual Strength Scale from: 0 to 28 ( Modafinil vs placebo | no estimate extracted | 1 study · 37 participants | Low |
Fatigue ‐ reduced activity Sub‐scale from Checklist Individual Strength Scale from: 0 to 21 ( Modafinil vs placebo | no estimate extracted | 1 study · 37 participants | Low |
Fatigue ‐ fatigue severity Sub‐scale from Checklist Individual Strength Scale from: 0 to 56 Modafinil vs placebo | no estimate extracted | 1 study · 37 participants | Low |
Adverse events ( Modafinil vs placebo | RR 2.79 | 1 study · 37 participants | Low |